They Buried it for COVID. Now They’re Doing It for Cancer

Cancer treatment in America runs on a simple, brutal economic model: the sicker we stay, the more money gets made. Chemotherapy drugs approved by the FDA in 2012 were priced at over $100,000 per patient per year—eleven out of twelve of them. Some immunotherapy treatments run $15,000 per dose. The cancer industry generates hundreds of billions of dollars annually, and every dollar of that revenue depends on patients continuing to need expensive, patented treatments. Which makes what a new study just documented all the more inconvenient for the people cashing those checks.

Published in April 2026 and now available as a preprint while undergoing peer review, a landmark study co-authored by Dr. Peter McCullough, Dr. Harvey Risch of Yale School of Public Health, and ten other researchers analyzed 197 cancer patients prescribed a combination of ivermectin and mebendazole—two decades-old, off-patent, dirt-cheap antiparasitic drugs. The results, as Nicolas Hulscher, MPH reported at Focal Points, are the kind that should be making front pages. At six-month follow-up, 84.4% of patients reported clinical benefit. Nearly half—48.4%—reported either tumor regression or no current evidence of disease. Another 36.1% reported stable disease. Only 15.6% reported progression. Side effects were mild and mostly gastrointestinal, with 93.6% of those who experienced them continuing treatment anyway.

To put those numbers in perspective: more than four out of five cancer patients reported improvement or stabilization. Half reported their cancer was gone or shrinking. With drugs that cost roughly $30 a dose. ---More...